{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T22:24:52Z","timestamp":1789770292804,"version":"4.0.1"},"reference-count":16,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T00:00:00Z","timestamp":1251763200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0006877","type":"journal-article","created":{"date-parts":[[2009,8,31]],"date-time":"2009-08-31T22:29:48Z","timestamp":1251757788000},"page":"e6877","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":74,"title":["Raltegravir Cerebrospinal Fluid Concentrations in HIV-1 Infection"],"prefix":"10.1371","volume":"4","author":[{"given":"Aylin","family":"Yilmaz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"Gissl\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Spudich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyn","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anura","family":"Jayewardene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Aweeka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard W.","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2009,9,1]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1056\/NEJM199803263381301","article-title":"Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.","volume":"338","author":"FJ Palella Jr","year":"1998","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/ana.10827","article-title":"Changing incidence of central nervous system diseases in the EuroSIDA cohort.","volume":"55","author":"A d'Arminio Monforte","year":"2004","journal-title":"Ann Neurol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"S294","DOI":"10.1086\/533419","article-title":"Antiretroviral therapy and central nervous system HIV type 1 infection.","volume":"197","author":"RW Price","year":"2008","journal-title":"J Infect Dis"},{"key":"ref4","article-title":"Defining and evaluating HIV-related neurodegenerative disease and its treatment targets: a combinatorial approach to use of cerebrospinal fluid molecular biomarkers.","author":"M Gissl\u00e9n","year":"2006","journal-title":"J Neuroimmune Pharmacology: in press"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/j.clinthera.2008.10.012","article-title":"Raltegravir: the first HIV integrase inhibitor.","volume":"30","author":"J Cocohoba","year":"2008","journal-title":"Clin Ther"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1056\/NEJMoa0708975","article-title":"Raltegravir with optimized background therapy for resistant HIV-1 infection.","volume":"359","author":"RT Steigbigel","year":"2008","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/sj.clpt.6100281","article-title":"Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.","volume":"83","author":"M Iwamoto","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"ref8","article-title":"Better Antiretroviral Penetration into the Central Nervous System Is Associated with Lower CSF Viral Load. Presented at: Conference of Retroviruses and Opportunistic Infections, Denver","author":"S Letendre","year":"2006"},{"key":"ref9","article-title":"The transport of anti-HIV drugs across blood-CNS interfaces: Summary of current knowledge and recommendations for further research.","author":"L Varatharajan","year":"2009","journal-title":"Antiviral Res"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/ana.410420502","article-title":"Measuring the \u201cviral load\u201d in cerebrospinal fluid in human immunodeficiency virus infection: window into brain infection?","volume":"42","author":"RW Price","year":"1997","journal-title":"Ann Neurol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3109\/00365517709091496","article-title":"Principles of albumin and IgG analyses in neurological disorders. I. Establishment of reference values.","volume":"37","author":"G Tibbling","year":"1977","journal-title":"Scand J clin Lab Invest"},{"key":"ref12","article-title":"Pharmacokinetics of Raltegravir in Individuals With UGT1A1 Polymorphisms.","author":"L Wenning","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1124\/dmd.107.016196","article-title":"Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme.","volume":"35","author":"K Kassahun","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"ref14","year":"2008"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/ana.410340307","article-title":"Cerebral white matter changes in acquired immunodeficiency syndrome dementia: alterations of the blood-brain barrier.","volume":"34","author":"C Power","year":"1993","journal-title":"Ann Neurol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1097\/QAI.0b013e318162754f","article-title":"Antiretroviral treatment effect on immune activation reduces cerebrospinal fluid HIV-1 infection.","volume":"47","author":"E Sinclair","year":"2008","journal-title":"J Acquir Immune Defic Syndr"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0006877","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T06:50:51Z","timestamp":1589007051000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0006877"}},"subtitle":[],"editor":[{"given":"Beatriz","family":"Grinsztejn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2009,9,1]]},"references-count":16,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2009,9,1]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0006877","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,9,1]]}}}